Compare HCA Health Inc (HCA) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Marvell Technology Inc — how do they compare? HCA Health Inc trades at $447.04 (market cap $96.35B), while Marvell Technology Inc trades at $270.45 (market cap $246.84B). The key difference: Marvell Technology Inc is far larger — about 2.6× HCA Health Inc's market cap, and HCA Health Inc pays the higher dividend (0.7%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Marvell Technology Inc for 42 Days on average.
| HCA | MRVL | |
|---|---|---|
Market Cap | $96.35B | $246.84B |
Volume | 1,079,453 | 29,003,830 |
Sector | Health | Technology |
52-Week High | $545.13 | $316.43 |
52-Week Low | $361.32 | $73.73 |
Typical Hold Time | 76 Days | 42 Days |
Enterprise Value | $146.88B | $248.19B |
Dividend Yield | 0.7% | 0.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $439.17, up 1.61% today, with a bullish technical signal and strong fundamental performance. Revenue grew to $75.6 billion in 2025, with net income reaching $6.78 billion, and the company has beaten EPS estimates for three consecutive quarters. Recent news includes an upcoming Q3 2026 earnings call and the completion of the College of Health Care Professions acquisition, highlighting operational expansion.
The outlook remains positive with a consensus price target of $461.12, though risks include ongoing legal investigations and high debt levels. Earnings growth and cost controls support upside potential, but investors should monitor regulatory developments and payer-mix pressures that could impact margins.
Marvell Technology (MRVL) trades at $284.68, down 0.81% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 expected at $1.1. Revenue growth is accelerating, driven by data center and custom AI chip demand, though current valuations are elevated with a P/E of 90.95. Recent news highlights a major Google deal and raised fiscal 2028 revenue guidance to $18 billion.
The outlook remains positive given robust AI infrastructure spending and management's optimistic forecasts. Key risks include high valuation multiples, competitive pressures, and execution challenges in scaling custom chip production. Analyst consensus is strongly bullish with a $327.86 price target, suggesting significant upside potential if growth targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
